Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

Rhea-AI Summary

Sagimet Biosciences (Nasdaq: SGMT) has announced its participation in the UBS Global Healthcare Conference. The clinical-stage biopharmaceutical company, which focuses on developing therapeutics for metabolic and fibrotic pathways, will engage in a fireside chat on Wednesday, November 13, 2024, at 5 p.m. PST in Rancho Palos Verdes, California.

The event will be accessible via webcast through Sagimet's website in the Investors & Media section, with replay availability for 90 days after the live presentation.

News Market Reaction – SGMT

+3.17%

+3.17% Session move

In the trading session that priced this news, SGMT gained 3.17%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN MATEO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, November 13, 2024 at 5 p.m. PST in Rancho Palos Verdes, California.

A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.

About Sagimet Biosciences 

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of MASH. FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. For additional information about Sagimet, please visit www.sagimet.com.

Contact:
Joyce Allaire 
LifeSci Advisors 
jallaire@lifesciadvisors.com

Source: Sagimet Biosciences Inc.

FAQ

When is Sagimet Biosciences (SGMT) presenting at the UBS Global Healthcare Conference 2024?

Sagimet Biosciences will present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 5 p.m. PST in Rancho Palos Verdes, California.

How long will the replay of Sagimet's (SGMT) UBS Conference presentation be available?

The webcast replay will be available for 90 days following the live event on Sagimet's website in the Investors & Media section.

Where can I watch Sagimet Biosciences' (SGMT) UBS Conference presentation?

The presentation can be viewed via webcast in the Investors & Media section of Sagimet's website at www.sagimet.com.

What type of presentation will Sagimet (SGMT) give at the UBS Healthcare Conference?

Sagimet Biosciences will participate in a fireside chat format presentation at the conference.